The first two authors contributed equally to this manuscript Transgenic mice that over-express connective tissue growth factor (CTGF) in fibroblasts under the control of an enhancer/promoter element of the Colta2 gene (Colla2-CTGF) recapitulate multiorgan fibrosis similar to fibrosis observed in Scleroderma (SSe). In this study we investigate the regulation of secreted protein acidic and rich in cysteine (Spare) and Ctgf siRNAs on the expression of several extracellular matrix components in the fibroblasts derived from Colla2-CTGF transgenie mice. Three fibroblast lines were obtained from each of wide type CS7BL/6 and CTGFtransgenic CS7BL/6, and were transfected with Spare siRNA or Ctgf siRNA. Real-time quantitative RT-PCR and Western blotting were used to examine the transcription and protein levels of type I collagen, CTGF and SPARC. Student's t-tests were used to determine the significance of the results. Our results showed that Colta2 and Ctgf increased expression at both transcriptional and translational levels in the fibroblasts from the Colla2-CTGF transgenic mice compared with those in the fibroblasts from their normal wild-type Iittermate. The treatment with Spare siRNA or Ctgf siRNA attenuated the mRNA and/or protein expression of the Colta2, Ctgf and Spare in these fibroblasts. Spare and Ctgf siRNAs also showed a reciprocal inhibition at transcript levels. Therefore, our results indicated that both SPARC and CTGF appeared to be involved in the same biological pathway, and they have the potential to serve as a therapeutic target for fibrotic diseases such as SSe.
Systemic sclerosis (SSc), also known as scleroderma, is a complex autoimmune disease characterized by skin and internal organ fibrosis. Currently, there is neither effective therapy nor effective prevention for this disease. Although the etiology of SSc is still unknown, both in vitro and in vivo studies have indicated that the extensive deposition of collagens, and other extracellular matrix (ECM) proteins by activated fibroblasts is a major pathologic property of SSc (1-2).
To better understand the pathogenic mechanisms and to find potential therapeutic targets of SSc, several kinds of animal models, including genetically modified mice harboring disruptions or manipulation of pivotal signaling pathways, have been established (2) (3) . Transforming growth factor P (TGFP) is a fibrotic growth factor. Over-activity ofTGFp signaling has been widely accepted to play important roles in the fibrosis of SSc (4) . Connective tissue growth factor (CTGF) is a downstream mediator ofTGFp signaling. Many of the profibrotic properties of TGFp are induced by the actions of CTGF (5) . ColJa2-CT.GFtransgenic mice that overexpress CTGF in fibroblasts under the collogen type I (Call a2) promoter showed an SSc-like fibrotic phenotype (6) . The animal models provide a platform for testing potential anti-fibrotic reagents for SSc. SPARC (secreted protein, acidic and rich in cysteine) is a matricellular component of the ECM. It participates in the modulation of cell-matrix interactions, cell adhesion, wound repair, and angiogenesis (7-9) and possibly plays an important role in fibrosis. Increased expression ofSPARC have been found in many fibrotic diseases including SSc, pulmonary fibrosis, renal interstitial fibrosis, hepatic cirrhosis, and atherosclerotic vascular lesions (10) (11) (12) (13) (14) . SPARC has shown the ability to interact with the TGFp signaling system through a TGFp receptor and Smad2/3-dependent pathway ( 15) .
In our previous studies, we observed that SPARC can regulate the expression of type 1 collagen, a major structural protein of the ECM, in normal human fibroblasts (16) . Moreover, after exogenous TGFp stimulation, SPARC siRNA showed a protective role against overexpression of collagen genes (16) . Specific inhibition of SPARC expression with siRNA led to a down-regulation of collagen and CTGF gene expression in SSc fibroblasts (17) . In order to evaluate the influence of the inhibition of Spare in the ColJa2-CTGF transgenic mouse model and its potential as a therapeutic target of SSc, an in vitro study was performed using the fibroblasts derived from the novel Call a2-CTGF transgenic mouse model to investigate the regulation of Spare siRNA on the expression of several ECM components, and to compare it with that of Ctgf siRNA.
MATERIALS AND METHODS

Cel/lines
Two fibroblast lines derived from skin biopsies of Colla2-CTGF transgenic (heterozygous) mice and wildtype littermate controls (wide type C57BL/6) (6) were used in experiments described here. The cultures were maintained in DMEM with 10% FCS and supplemented with antibiotics (50 U/ml penicillin and 50 ug/rnl streptomycin). Fifth-passage fibroblast cells were seeded at a density of 5 x 10' cells in 25-cm 2 flasks and grown until confluence.
Transient trans(eetion with siRNA
Double-stranded ON-TARGETplus siRNAs of murine Spare and Ctgf were purchased from DHARMACON (Lafayette, CO). The corresponding target sequences are 5'-GCACCACACGUUUCUUUG -3' for Spare and 5'-GCACCAGUGUGAAGACAUA -3' for Ctgf, respectively. The culture medium in each culture flask with confluent fibroblasts was replaced with Opti-MEM I medium (Invitrogen, Carlsbad, CA) without FCS and antibiotics. The fibroblasts were transfected with Spare siRNA or Ctgf siRNA, using Metafectene (Biontex, Munich, Germany) in a concentration of 3 ug siRNA per ml medium. Fibroblasts with Non-Targeting siRNA treatment were used as negative control. After 8 hours, the culture medium was replaced with DMEM. The cells transfected with siRNA were examined after 72 hours of transfection and used for RNA expression and protein assays.
Determination of gene expression by quantitative RT-PCR
Quantitative real-time RT-PCR was performed using an ABI 7900 Sequence Detector System (Applied Biosystems, Foster City, CA). The specific primers and probes for each gene (Colla2, Ctgf, and Spare) were purchased from the Assays-on-Demand product line (Applied Biosystems). Total RNA from each sample was extracted from the cultured fibroblasts using RNeasy Mini Kit (Qiagen, Valencia, CA). Complementary DNA (eDNA) was synthesized using MultfScribe" Reverse Transcriptase (Applied Biosystems). Synthesized cDNAs were mixed with primers/probes in 2 x TaqMan universal PCR buffer and then assayed on an ABI 7900 sequence detector. The data obtained from the assays were analyzed with SDS 2.2 software (Applied Biosystems). The amount of total RNA in each sample was normalized with Gapdh transcript levels.
Western blot analysis
The cellular Iysates extracted from the above cultured fibroblasts were used for protein assays. The protein concentration was determined by a spectrophotometer using Bradford protein assay kit (Bio-Rad Laboratories, Hercules, CA). Equal amounts of protein from each sample were subjected to sodium dodecyl suIfatepolyacrylamide gel electrophoresis. Resolved proteins were transferred onto PVDF membrane and incubated with respective primary antibodies, including anti-type I collagen antibody (Biodesign International, Saco, ME), anti-CTGF antibody (GeneTex Inc, San Antonio, TX), and anti-SPARC antibody (R&D Systems Inc, Minneapolis, MN). Mouse p-actin (Alexis Biochemicals, San Diego, CA) was used as an internal control. The secondary antibody was peroxidase-conjugated antirabbit, anti-goat, or anti-mouse IgG. Specific proteins were detected by chemiluminescence using an enhanced chemiluminescence system (Amersham, Piscataway, NJ). The intensity of the bands was quantified using ImageQuant software (Molecular Dynamics, Sunnyvale, CA).
RESULTS
Colla2, Ctgfand Spare expression in Colla2-CTGF transgenic mice fibroblasts
As measured by quantitative real-time RT-PCR, Col Ja2, Ctgf and Spare showed increased gene expression in the fibroblasts from Colla2-CTGF transgenic mice compared with those from wildtype littermate controls (wild type) (Fig. I) . The fold changes of each gene in transgenic fibroblasts were 2.11±0.01 for Colla2, 5.77±0.36 for Ctgf, and 1.66±0.18 for Spare, respectively.
Transfection efficiency
Two methods were used for measuring transfection efficiency of siRNA. First, the fibroblasts were transfected with fluorescein-labeled non-silencing siRNA, and then examined under fluorescence COll1)arison betMlen wildtype and transgenic nice " microscopy which showed ,...,80% transfection efficiency by direct cell counting. Second, the fibroblasts from GFP transgenic C57BL/6 mouse (The Jackson Laboratory, Bar Harbor, Maine) were transfected with specific siRNA of GFP, and then examined to see how many cells responded with decreased levels of GFP. A similar efficiency of transfection was seen (Fig. 2) .
Gene expression of Colla2, Ctgf and Spare after transfection of siRNAs in wild type and Colla2-CTGF transgenic mice fibroblasts Seventy-two hours after transfection, the reduction of Ctgf (73% and 85% in wide type and transgenic type, respectively) by Ctgf siRNA and Spare (69% and 82% in wide type and transgenic type, respectively) by Spare siRNA were observed in the two fibroblast lines from wide type or Ctgf transgenic mice (Table I and Fig. 3 ). Interestingly, the expression ofCtgfand Spare showed a reciprocal down-regulation by Spare siRNA and Ctgf siRNA (26% and 62% down-regulation of Ctgf by Spare siRNA in wide type and transgenic, respectively; 29% and 53% down-regulation of Spare by Ctgf siRNA in wide type and transgenic, respectively) (Table I and Fig. 3 ). In addition to the expression of Ctgf and Spare, the Col Ja2 also showed to be consistently down-regulated in all the fibroblasts after treated either by Ctgf siRNA or Spare siRNA (Table I and Fig. 3 ).
Protein expression~{COLl. CTGF and SPARC in the fibroblasts with or without siRNA treatment
The expression of the three ECM components at protein level was examined by Western blot analysis. Collagen type I and CTGF showed increased expression in the fibroblasts of Colla2-CTGF transgenic mice compared with those in the cells from their normal littermate (wide type) ( Fig. 4) , which was consistent with their increased expression at the mRNA level. SPARC protein did not show significant reduction in the fibroblasts of ColI a2-CTGF transgenic mice, although its transcriptional level was lower.
Western blots also showed that the expression of Collagen type I, CTGF and SPARC were decreased after Ctgf siRNA or Spare siRNA treatment in all fibroblast lines except for Spare expression in the GFP transgenic mouse flbroblasts without GFP siRNA GFP transqenlc mouse fibroblasts with GFP siRNA 
DISCUSSION
fibroblasts transfected with Ctgf siRNA (Fig. 4) .
The down-regulation of CTGF protein by Ctgf siRNA was obviously less efficient than that of Spare protein by Spare siRNA (27% vs 86%, and 39% vs 92% in wild type and transgenic fibroblasts, respectively), although transcriptional levels of inhibition by their respective siRNAs were similar between Ctgf and Spare, Spare siRNA also downregulated Ctgf, while Ctgf siRNA did not show a reciprocal inhibition to Spare protein. In addition, the reduction of Coli a2 protein by Ctgf siRNA was less than that by Spare (37% vs 47%, 21% vs 35% in wide type and transgenic fibroblasts, respectively) ( Fig. 4.) .
Scleroderma is a devastating fibrotic disease which confers a high risk of mortality. No optimal therapy for reducing excessive collagen production in this disease is available (17) . Animal model studies are crucial in finding therapeutic targets in SSc (18) .
Recently, Colla2-CTGF transgenic mouse model was generated, that constitutively over-expressed CTGF specifically in fibroblasts (6) . These mice displayed features similar to human scleroderma, including dermal fibrosis and lung fibrosis, and thus provided useful tools in the study offibrogenesis and identification of possible therapeutic targets. Extensive deposition of collagens and other ECM proteins represent biomarkers for activated fibroblasts of SSc. SPARC and CTGF are two such ECM proteins important in regulating the production of collagen. Several mechanisms of such regulation have been explored, such as through SPARC and/or CTGF directly down-stream regulation or feedback control ofTGF~signaling transduction, and through direct binding to TGF~receptor or TGF~itself (15, (19) (20) (21) (22) (23) . In our previous study, it was shown that SPARC siRNA could attenuate the production of some ECM components, such as type 1 and 3 collagens, SPARC and CTGF in human normal and SSc fibroblasts (16) (17) 23) . We and others also showed that the blockade ofCTGF expression either by CTGF siRNA, or its antisense oligonucleotide or corresponding antibody, can block TGFp-induced collagen production and/or fibronectin expression (23) (24) (25) (26) . We hereby further validated the anti-fibrotic effect of CTGF and SPARC inhibitors in profibrotic fibroblasts of CoIl a2-CTGF transgenic mice that constantly over-express CTGF and collagens.
Our studies indicate that, similar to human fibroblasts, Spare siRNA and Ctgf siRNA downregulated the expression of collagen in mice fibroblasts of both wild type and CoIl a2-CTGF transgenic types at both the transcriptional and translational levels (Table I, Figs. 3 and 4 ). Since parallel expression of Ctgf, Spare and collagen in CoIla2-CTGF transgenic mice fibroblasts suggested that all three genes are involved in Ctgf-driven biological pathways, attenuation of over-expressed collagen type I in Colla2-CTGF transgenic mouse fibroblasts by Spare siRNA is likely mediated by Ctgf function.
Although mRNA expression levels of Spare and Ctgf showed a reciprocal inhibition of these two genes by corresponding siRNA treatment in mouse fibroblasts, protein expression of these two appeared different. Spare siRNA down-regulated CTGF protein in both wild type and transgenic mouse fibroblasts. In contrast, Ctgf siRNA did not show down-regulatory effect on the SPARC protein expression in the fibroblasts. Discordant expression levels of mRNA and protein of Spare in both wild type and transgenic fibroblasts treated with Ctgf siRNA may reflect translational efficiency in the cells. On the other hand, concordant regulation of mRNA and protein ofCtgfby Spare siRNA supports our previous finding in human fibroblasts, in which SPARC showed as an upstream regulator ofCTGF in response to TGFp stimulation (23) . It is worth noting that an up-regulated gene expression level of Spare was observed in the fibroblasts of CoIla2-CTGF transgenic mice. Along with the reciprocal inhibition of Spare and Ctgf genes by corresponding siRNA treatment in mouse fibroblasts, these observations further suggested a mutual regulatory effect between SPARC and CTGF in the ECM compartment.
In conclusion, the fibroblasts from CoIla2-CTGF transgenic mice showed profibrotic features, which can be ameliorated by Inhibition of Spare or Ctgf expression using their corresponding siRNAs. Spare and Ctgf siRNAs showed a reciprocal inhibition in transcript levels, and Spare siRNA also reduced the protein level of CTGF. The present in vitro study using fibroblasts from Colla2-CTGF transgenic mouse model provides useful and potentially sufficient information for in vivo research to proceed.
